ReShape Lifesciences (Formally known as EnteroMedics)

280 articles about ReShape Lifesciences (Formally known as EnteroMedics)

• EnteroMedics Announces Exercise of Over-Allotment Option Bringing Total Proceeds of Recent Offering to Approximately $29.8 Million

  12/13/2010

• EnteroMedics Announces Pricing of $25.9 Million Public Offering of Common Stock and Warrants

  12/9/2010

• EnteroMedics Announces Data From Australian Patient Cohort in EMPOWER Study and From Caloric Intake Study

  11/9/2010

• EnteroMedics Announces Adjournment of Special Stockholder Meeting Until 10:00 a.m. Central Time on October 29, 2010

  10/25/2010

• EnteroMedics Announces Updated Data from VBLOC-DM2, EMPOWER and VBLOC RF2 Studies

  10/20/2010

• EnteroMedics Completes $6.3 Million Convertible Preferred Stock Offering

  9/30/2010

• FDA OKs New Clinical Trial For EnteroMedics Anti-Obesity Device

  8/20/2010

• EnteroMedics Reports Second Quarter 2010 Financial Results

  7/23/2010

• EnteroMedics Announces 1-for-6 Reverse Split of Common Stock

  6/30/2010

• EnteroMedics Shares Soar 108% on Promise of Obesity Device; Jun 22, 2010 5:46pm EDT

  6/23/2010

• EnteroMedics Reports First Quarter 2010 Financial Results

  4/22/2010

• EnteroMedics Extends Neuroblocking Technology Research and Development Collaboration With Mayo Clinic

  3/18/2010

• EnteroMedics Announces Submission of IDE Application for Maestro RC System

  3/16/2010

• EnteroMedics Appoints Dr. Scott Shikora as Consulting Chief Medical Officer

  2/23/2010

• EnteroMedics Plans New Clinical Trial

  2/1/2010

• EnteroMedics Announces Transfer of its Common Stock to the Nasdaq Capital Market

  1/22/2010

• EnteroMedics Announces $4.8 Million Financing

  1/15/2010

• EnteroMedics Announces Weight Loss, Hypertension and Diabetes Data from EMPOWER and ENABLE Studies

  1/14/2010

• EnteroMedics to Present at the 28th Annual J.P. Morgan Healthcare Conference

  1/6/2010

• EnteroMedics Receives Notice of NASDAQ Listing Deficiencies

  11/20/2009